JP4243484B2 - カンプトテシン誘導体 - Google Patents

カンプトテシン誘導体 Download PDF

Info

Publication number
JP4243484B2
JP4243484B2 JP2002557393A JP2002557393A JP4243484B2 JP 4243484 B2 JP4243484 B2 JP 4243484B2 JP 2002557393 A JP2002557393 A JP 2002557393A JP 2002557393 A JP2002557393 A JP 2002557393A JP 4243484 B2 JP4243484 B2 JP 4243484B2
Authority
JP
Japan
Prior art keywords
cpt
hydroxy
amino
camptothecin
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002557393A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004521105A (ja
JP2004521105A5 (https=
Inventor
ヤン，リ−シ
パン，シャンダオ
ワン，ヒュイジュアン
Original Assignee
カリフォルニア パシフィック メディカル センター
カトリック ヘルスケア ウエスト，ドゥーイング ビジネス アズ セント メアリーズ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カリフォルニア パシフィック メディカル センター, カトリック ヘルスケア ウエスト，ドゥーイング ビジネス アズ セント メアリーズ メディカル センター filed Critical カリフォルニア パシフィック メディカル センター
Publication of JP2004521105A publication Critical patent/JP2004521105A/ja
Publication of JP2004521105A5 publication Critical patent/JP2004521105A5/ja
Application granted granted Critical
Publication of JP4243484B2 publication Critical patent/JP4243484B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2002557393A 2001-01-18 2001-12-20 カンプトテシン誘導体 Expired - Fee Related JP4243484B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26304001P 2001-01-18 2001-01-18
US09/797,769 US6350756B1 (en) 2001-01-18 2001-03-01 Camptothecin derivatives
PCT/US2001/050288 WO2002056885A1 (en) 2001-01-18 2001-12-20 Camptothecin derivatives

Publications (3)

Publication Number Publication Date
JP2004521105A JP2004521105A (ja) 2004-07-15
JP2004521105A5 JP2004521105A5 (https=) 2005-12-22
JP4243484B2 true JP4243484B2 (ja) 2009-03-25

Family

ID=26949624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002557393A Expired - Fee Related JP4243484B2 (ja) 2001-01-18 2001-12-20 カンプトテシン誘導体

Country Status (14)

Country Link
US (2) US6350756B1 (https=)
EP (1) EP1353673B1 (https=)
JP (1) JP4243484B2 (https=)
KR (1) KR100879489B1 (https=)
CN (1) CN100406013C (https=)
AT (1) ATE359786T1 (https=)
AU (1) AU2002243367B2 (https=)
CA (1) CA2434747C (https=)
DE (1) DE60128003T2 (https=)
ES (1) ES2284716T3 (https=)
IL (2) IL156967A0 (https=)
MX (1) MXPA03006405A (https=)
NZ (1) NZ527078A (https=)
WO (1) WO2002056885A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6855720B2 (en) * 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6403604B1 (en) * 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6699875B2 (en) * 2002-05-06 2004-03-02 The Stehlin Foundation For Cancer Research Cascade esters of camptothecins and methods of treating cancer using these compounds
US6703399B2 (en) 2002-05-06 2004-03-09 The Stehlin Foundation For Cancer Research Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds
US6933302B2 (en) * 2002-06-03 2005-08-23 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
AU2003243397A1 (en) * 2002-06-03 2003-12-19 California Pacific Medical Center Homo-camptothecin derivatives
US20050129719A1 (en) * 2003-12-15 2005-06-16 Yu-Fang Hu Concentrated emulsion formulation for silatecan
RU2413731C2 (ru) * 2004-04-09 2011-03-10 Чугаи Сейяку Кабусики Кайся Новые растворимые в воде пролекарства
US20060003976A1 (en) * 2004-06-04 2006-01-05 Yuehua Zhang Cholesterol/bile acid/bile acid derivative-modified therapeutic drug compounds
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US20090105202A1 (en) * 2005-10-20 2009-04-23 California Pacific Medical Center Androsterone Derivatives and Method of Use thereof
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
WO2012134446A1 (en) * 2011-03-29 2012-10-04 SUTTER WEST BAY HOSPITALS doing business as CALIFORNIA PACIFIC MEDICAL CENTER Epiandrosterone and/or androsterone derivatives and method of use thereof
TWI549679B (zh) 2011-11-03 2016-09-21 台灣微脂體股份有限公司 疏水性喜樹鹼衍生物之醫藥組合物
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
CN102516258B (zh) * 2011-11-11 2014-06-25 正大天晴药业集团股份有限公司 水溶性维生素e衍生物修饰的脂溶性抗癌药物化合物和制剂、该化合物的制备方法及应用
CN104163823B (zh) * 2014-04-30 2016-03-09 浙江工业大学 一种喜树碱与青蒿琥酯偶联物及其制备方法与应用
CN110590796B (zh) * 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用
MX2022000474A (es) 2019-07-11 2022-03-11 Sun Pharma Advanced Res Co Ltd Derivados de camptotecina con un resto disulfuro y un resto piperazina.
TW202547842A (zh) 2021-04-29 2025-12-16 愛爾蘭商艾伯維製造管理無限公司 抗c-Met抗體藥物結合物
WO2023150899A1 (en) * 2022-02-08 2023-08-17 Canwell Biotech Limited Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof
PE20252282A1 (es) 2022-10-09 2025-09-18 Lanova Medicines Ltd Compuestos, composiciones y metodos
CN117285540B (zh) * 2023-09-27 2025-07-11 中国海洋大学 12-位取代的喜树碱衍生物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JP2524803B2 (ja) * 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体およびその製造法
JP2524804B2 (ja) * 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体及びその製造法
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
GB9504065D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
JPH08333370A (ja) 1995-06-08 1996-12-17 Kyorin Pharmaceut Co Ltd 水に可溶な新規フルオロエチルカンプトテシン誘導体、及びその製造方法
US6339091B1 (en) 1995-06-21 2002-01-15 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Comptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues
AU7732996A (en) 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6096336A (en) 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US5731316A (en) 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
IL127800A (en) 1996-08-19 2005-11-20 Bionumerik Pharmaceuticals Inc Highly lipophilic 7-substituted camptothecin derivatives and pharmaceutical compositions containing them
EP0961619A4 (en) 1996-09-27 2001-09-26 Bristol Myers Squibb Co HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS
ATE210673T1 (de) 1996-09-30 2001-12-15 Bayer Ag Glycokonjugate von modifizierten camptothecin- derivaten (20-o-verknüpfung)
TW464652B (en) 1996-10-30 2001-11-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
UA57757C2 (uk) 1996-12-20 2003-07-15 Сос'Єте Де Консей Де Решерш Е Даплікасьон С'Єнтіфік (С.К.Р.А.С.) Аналоги камптотецину, спосіб їх отримання (варіанти) і фармацевтична композиція
US6169080B1 (en) * 1997-02-13 2001-01-02 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
ATE329903T1 (de) * 1997-02-14 2006-07-15 Bionumerik Pharmaceuticals Inc Hochgradig lipophile camptothecin-derivate
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721070D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6057303A (en) 1998-10-20 2000-05-02 Bionumerik Pharmaceuticals, Inc. Highly lipophilic Camptothecin derivatives
US6207832B1 (en) 1999-04-09 2001-03-27 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
WO2000066127A1 (en) 1999-05-04 2000-11-09 Bionumerik Pharmaceuticals, Inc. Novel highly lipophilic camptothecin analogs
US6765019B1 (en) 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
GB0119578D0 (en) 2001-08-10 2001-10-03 Pharmacia & Upjohn Spa Fluoro linkers

Also Published As

Publication number Publication date
CA2434747C (en) 2012-02-07
ES2284716T3 (es) 2007-11-16
IL156967A (en) 2009-08-03
CN100406013C (zh) 2008-07-30
CA2434747A1 (en) 2002-07-25
JP2004521105A (ja) 2004-07-15
ATE359786T1 (de) 2007-05-15
WO2002056885A1 (en) 2002-07-25
KR100879489B1 (ko) 2009-01-20
IL156967A0 (en) 2004-02-08
AU2002243367B2 (en) 2006-10-05
DE60128003T2 (de) 2007-12-27
DE60128003D1 (en) 2007-05-31
EP1353673B1 (en) 2007-04-18
CN1553802A (zh) 2004-12-08
US6350756B1 (en) 2002-02-26
NZ527078A (en) 2005-12-23
MXPA03006405A (es) 2004-12-02
EP1353673A1 (en) 2003-10-22
USRE39707E1 (en) 2007-06-26
KR20040035588A (ko) 2004-04-29

Similar Documents

Publication Publication Date Title
JP4243484B2 (ja) カンプトテシン誘導体
US8158809B2 (en) Podophyllotoxin derivatives
AU2002243367A1 (en) Camptothecin derivatives
JP4584538B2 (ja) 窒素を基礎とするカンプトテシン誘導体
KR101320160B1 (ko) 화학방사선증감제로서의 캄프토테신 유도체
US6855720B2 (en) Nitrogen-based camptothecin derivatives
US20040034050A1 (en) Homo-camptothecin derivatives
AU2002250039A1 (en) Nitrogen-based camptothecin derivatives

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090105

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120109

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130109

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees